ArriVent BioPharma, Inc. Common Stock
NASDAQ:AVBPBiotechnology
+$0.44 today
- Market cap
- $563.78M
- Beta
- 1.42
- P/E (TTM)
- -9.8
- EPS (TTM)
- -$3.22
Volume 2.70M
Average 0.50M
AVBP Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
ArriVent BioPharma, Inc. Common StockNASDAQ: AVBP
Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026
Selling, general & admin grows, but more slowly than its trailing trend
Q1 FY2026 selling, general & admin of $8.49M rose 54.9% year over year, behind the +59.1% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 27.8% from the prior quarter. Over 3 fiscal years it compounded at +55.2% a year.
Context
- Selling, general & admin increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate from 7 analysts of $0 (-100.0%) for the fiscal year ending Dec 2026, a slowdown from the +58.0% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $8.49M+27.8% QoQ
- Last fiscal yearDec 2025
- $24.18M+58.0% YoY
- LTMMar 2026
- $27.19M+59.1% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +54.9% | -100.0% | -154.9 pp |
| 1 year | +58.0% | -100.0% | -158.0 pp |
| 3-year CAGR | +55.2% | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 24.18M USD
- Year-over-year change
- +58.0%
- 4-year CAGR
- +80.8%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 24.18M | +58.0% |
| FY2024 | 2024-12-31 | 15.3M | +57.7% |
| FY2023 | 2023-12-31 | 9.71M | +49.9% |
| FY2022 | 2022-12-31 | 6.47M | +186.2% |
| FY2021 | 2021-12-31 | 2.26M | — |
Selling, General & Admin vs competitors
How AVBP compares with its peers on the latest reported figures
- AVBP's LTM Mar 2026 selling, general & admin of $27.19M is the 10th highest of the 11 companies compared; the peer median is $70.72M.
- Its year-over-year change of +59.1% is the 2nd highest of 11, against a peer median of +7.8%.
- Over three fiscal years its annual growth of +55.2% compares with a peer median of +4.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jul 2026 | $533.92M | +3.0% | +4.1% | 21.9% | |
| LTM Jun 2026 | $281.09M | -1.1% | +2.3% | 62.5% | |
| LTM Jun 2026 | $158.59M | +32.6% | +68.1% | 93.3% | |
| LTM Jun 2025 | $96.73M | -21.2% | -8.8% | 16.1% | |
| LTM Mar 2026 | $72.24M | -5.3% | -7.5% | 31.8% | |
| LTM Mar 2026 | $69.19M | +65.4% | +42.7% | 30.7% | |
| LTM Sep 2026 | $44.05M | +16.1% | +5.3% | — | |
| LTM Mar 2026 | $33.29M | +12.6% | +9.8% | — | |
| LTM Mar 2026 | $31.48M | +21.6% | +23.3% | — | |
| LTM Mar 2026 | $27.19M | +59.1% | +55.2% | — | |
| LTM Mar 2026 | $15.86M | -38.3% | -16.4% | — | |
| Peer median (excluding AVBP) | $70.72M | +7.8% | +4.7% | 31.3% | |
Competitors are the stored peer set for AVBP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 6.43M | 30.43M | 64.88M | 79M | 153.35M |
| Selling, General & Admin | 2.26M | 6.47M | 9.71M | 15.3M | 24.18M |
| Operating Expenses | 8.7M | 36.91M | 74.59M | 94.31M | 177.53M |
| Depreciation & Amortization | 0 | 36.91M | 0 | 0 | 0 |
| EBITDA | (51.61M) | 0 | (69.33M) | (80.49M) | (166.31M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (8.7M) | (36.91M) | (74.59M) | (94.31M) | (177.53M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 0 | 5.26M | 13.82M | 11.23M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (42.91M) | 0 | 5.26M | 13.82M | 11.23M |
| Income Before Tax | (51.61M) | (36.91M) | (69.33M) | (80.49M) | (166.31M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (51.61M) | (36.91M) | (69.33M) | (80.49M) | (166.31M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (40.44) | (1.10) | (2.17) | (2.56) | (4.32) |
| EPS (Diluted) | (40.44) | (1.10) | (2.17) | (2.56) | (4.32) |
| Weighted Avg Shares | 1.28M | 33.49M | 31.96M | 31.47M | 38.46M |
| Weighted Avg Shares (Diluted) | 1.28M | 33.49M | 31.96M | 31.47M | 38.46M |
ArriVent BioPharma, Inc. Common Stock
NASDAQ:AVBP
Intrinsic Alpha fair value
Locked
Current Price
$10.90
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.